Arshad M. Khanani

4.8k total citations · 3 hit papers
88 papers, 2.1k citations indexed

About

Arshad M. Khanani is a scholar working on Ophthalmology, Radiology, Nuclear Medicine and Imaging and Molecular Biology. According to data from OpenAlex, Arshad M. Khanani has authored 88 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 83 papers in Ophthalmology, 51 papers in Radiology, Nuclear Medicine and Imaging and 24 papers in Molecular Biology. Recurrent topics in Arshad M. Khanani's work include Retinal Diseases and Treatments (72 papers), Retinal Imaging and Analysis (42 papers) and Retinal and Optic Conditions (38 papers). Arshad M. Khanani is often cited by papers focused on Retinal Diseases and Treatments (72 papers), Retinal Imaging and Analysis (42 papers) and Retinal and Optic Conditions (38 papers). Arshad M. Khanani collaborates with scholars based in United States, Switzerland and United Kingdom. Arshad M. Khanani's co-authors include Aamir Aziz, Charles C. Wykoff, Sunil Patel, Pravin U. Dugel, Jeffrey S. Heier, V. Diana, Carl J. Danzig, Aaron Osborne, Jayashree Sahni and David Eichenbaum and has published in prestigious journals such as The Lancet, SHILAP Revista de lepidopterología and Ophthalmology.

In The Last Decade

Arshad M. Khanani

83 papers receiving 2.0k citations

Hit Papers

The real-world efficacy a... 2023 2026 2024 2023 2023 2024 25 50 75
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study – 6 month results
    2023 90 citations Arshad M. Khanani, Aamir Aziz et al. profile →
  2. Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial
    2023 82 citations David R. Lally, Jason Hsu et al. profile →
  3. Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: a phase 1/2a dose-escalation study
    2024 46 citations Jeffrey S. Heier, Arshad M. Khanani et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Arshad M. Khanani United States 25 1.8k 1.2k 594 127 80 88 2.1k
John A. Wells United States 22 2.4k 1.4× 1.9k 1.6× 693 1.2× 88 0.7× 126 1.6× 46 2.9k
Catherine Meyerle United States 24 2.9k 1.6× 1.8k 1.5× 523 0.9× 98 0.8× 76 0.9× 50 3.1k
K V Chalam United States 26 1.6k 0.9× 1.1k 0.9× 421 0.7× 46 0.4× 140 1.8× 106 2.0k
Philipp S. Muether Germany 27 1.3k 0.7× 1.1k 1.0× 296 0.5× 78 0.6× 109 1.4× 55 1.7k
Yit C. Yang United Kingdom 26 1.9k 1.1× 1.3k 1.1× 363 0.6× 39 0.3× 130 1.6× 89 2.2k
J. Jill Hopkins United States 14 2.6k 1.5× 2.1k 1.8× 531 0.9× 47 0.4× 82 1.0× 23 2.8k
Kameran Lashkari United States 18 822 0.5× 550 0.5× 704 1.2× 177 1.4× 79 1.0× 59 1.6k
Ryo Obata Japan 22 1.0k 0.6× 730 0.6× 353 0.6× 51 0.4× 62 0.8× 117 1.8k
Wenzhen Yu China 21 556 0.3× 391 0.3× 503 0.8× 107 0.8× 51 0.6× 69 1.1k
Muh‐Shy Chen Taiwan 23 804 0.5× 642 0.5× 291 0.5× 53 0.4× 62 0.8× 59 1.2k

Countries citing papers authored by Arshad M. Khanani

Since Specialization
Citations

This map shows the geographic impact of Arshad M. Khanani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Arshad M. Khanani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Arshad M. Khanani more than expected).

Fields of papers citing papers by Arshad M. Khanani

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Arshad M. Khanani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Arshad M. Khanani. The network helps show where Arshad M. Khanani may publish in the future.

Co-authorship network of co-authors of Arshad M. Khanani

This figure shows the co-authorship network connecting the top 25 collaborators of Arshad M. Khanani. A scholar is included among the top collaborators of Arshad M. Khanani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Arshad M. Khanani. Arshad M. Khanani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Eichenbaum, David, Arshad M. Khanani, Dante J. Pieramici, et al.. (2025). Phase 2 Study of the Anti-High Temperature Requirement A1 (HtrA1) Fab Galegenimab (FHTR2163) in Geographic Atrophy Secondary to Age-Related Macular Degeneration. American Journal of Ophthalmology. 275. 14–26.
3.
Danzig, Carl J., Christiana Dinah, Faruque Ghanchi, et al.. (2025). Faricimab Treat-and-Extend Dosing for Macular Edema Due to Retinal Vein Occlusion. Ophthalmology Retina. 9(9). 848–859. 2 indexed citations
4.
Goldberg, Roger A., Karl G. Csaky, Arshad M. Khanani, et al.. (2024). Resolution of Angiographic Macular Leakage with Faricimab versus Aflibercept in Patients with Diabetic Macular Edema in YOSEMITE/RHINE. Ophthalmology Retina. 9(6). 515–526. 1 indexed citations
5.
Ehlers, Justis P., Leina Lunasco, Peter K. Kaiser, et al.. (2024). Compartmental Exudative Dynamics in Neovascular Age-Related Macular Degeneration. Ophthalmology Retina. 8(8). 765–777. 12 indexed citations
6.
Khanani, Arshad M., Peter K. Kaiser, Margaret Chang, et al.. (2024). Vision Loss Reduction with Avacincaptad Pegol for Geographic Atrophy. Ophthalmology Retina. 8(11). 1052–1060. 9 indexed citations
7.
Khanani, Arshad M., Srinivas R. Sadda, David Sarraf, et al.. (2024). Effect of Brolucizumab and Aflibercept on the Maximum Thickness of Pigment Epithelial Detachments and Sub-Retinal Pigment Epithelium Fluid in HAWK and HARRIER. Ophthalmology Retina. 9(1). 13–21. 2 indexed citations
8.
Tadayoni, Ramin, Liliana P Paris, Carl J. Danzig, et al.. (2024). Efficacy and Safety of Faricimab for Macular Edema due to Retinal Vein Occlusion. Ophthalmology. 131(8). 950–960. 29 indexed citations
9.
Wykoff, Charles C., Hidetaka Matsumoto, Mark Barakat, et al.. (2023). RETINAL VASCULITIS OR VASCULAR OCCLUSION AFTER BROLUCIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina. 43(7). 1051–1063. 21 indexed citations
10.
Khanani, Arshad M., David S. Boyer, Charles C. Wykoff, et al.. (2023). Safety and efficacy of ixoberogene soroparvovec in neovascular age-related macular degeneration in the United States (OPTIC): a prospective, two-year, multicentre phase 1 study. EClinicalMedicine. 67. 102394–102394. 35 indexed citations
11.
Aziz, Aamir, et al.. (2023). Emerging Treatment Options for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration. Clinical ophthalmology. Volume 17. 321–327. 32 indexed citations
12.
13.
Aziz, Aamir, et al.. (2021). Faricimab: An Emerging Therapy for the Treatment of Neovascular Age-related Macular Degeneration. European Ophthalmic Review. 15(1). 23–23. 1 indexed citations
14.
Khanani, Arshad M., Jeffrey S. Heier, Carlos Quezada-Ruiz, et al.. (2021). Faricimab in Neovascular Age-Related Macular Degeneration: 1-Year Efficacy, Safety, and Durability in the Phase 3 TENAYA and LUCERNE Trials. Investigative Ophthalmology & Visual Science. 62(8). 428–428. 5 indexed citations
15.
Khanani, Arshad M., Aamir Aziz, Christina Y. Weng, et al.. (2021). Port delivery system: a novel drug delivery platform to treat retinal diseases. Expert Opinion on Drug Delivery. 18(11). 1571–1576. 19 indexed citations
16.
Aziz, Aamir, Arshad M. Khanani, Nikolas London, et al.. (2021). Real World Efficacy and Safety of Brolucizumab in Neovascular AMD: The REBEL Study. Investigative Ophthalmology & Visual Science. 62(8). 451–451. 8 indexed citations
17.
Pieramici, Dante J., Arshad M. Khanani, Flávia Brunstein, et al.. (2020). Phase 1 safety study of intravitreal (ITV) Anti-High Temperature Requirement A1 (aHtrA1), a novel serine protease inhibitor, in patients with Geographic Atrophy (GA). Investigative Ophthalmology & Visual Science. 61(7). 1942–1942. 1 indexed citations
18.
Haug, Sara J., Günay Uludağ, Muhammad Sohail Halim, et al.. (2020). Retinal arterial occlusive vasculitis following intravitreal brolucizumab administration. American Journal of Ophthalmology Case Reports. 18. 100680–100680. 113 indexed citations
19.
Khanani, Arshad M., et al.. (2016). A Prospective Masked Clinical Assessment of Inflammation After Intravitreal Injection of Ranibizumab or Aflibercept. Journal of Ocular Pharmacology and Therapeutics. 32(4). 216–218. 24 indexed citations
20.
Khanani, Arshad M., Lauren Hill, & Lisa Tuomi. (2015). Improvement in visual acuity following ranibizumab treatment in neovascular age-related macular degeneration patients with large pigment epithelial detachments: a subgroup analysis of the HARBOR study. Investigative Ophthalmology & Visual Science. 56(7). 5363–5363. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by John A. Wells Breakdown of academic impact, for papers by Catherine Meyerle Breakdown of academic impact, for papers by K V Chalam Breakdown of academic impact, for papers by Philipp S. Muether Breakdown of academic impact, for papers by Yit C. Yang Breakdown of academic impact, for papers by J. Jill Hopkins Breakdown of academic impact, for papers by Kameran Lashkari Breakdown of academic impact, for papers by Ryo Obata Breakdown of academic impact, for papers by Wenzhen Yu Breakdown of academic impact, for papers by Muh‐Shy Chen
Rankless by CCL
2026